As a result, our studies identify NPM1–TYK2 as a novel fusion oncogene and suggest that inhibition of fusion homodimerization could be a precision therapeutic approach in cutaneous T-cell lymphoma patients expressing this chimera. The gene discussed is TYK2; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.